Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	25.25M
Revenue (ttm)	11.17M
Net Income (ttm)	-66.17M
Shares Out	38.26M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,242
Open	0.630
Previous Close	0.638
Day's Range	0.630 - 0.670
52-Week Range	0.545 - 1.560
Beta	0.93
Analysts	Hold
Price Target	1.25 (+89.39%)
Earnings Date	Nov 7, 2024

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2023, Bolt Biotherapeutics's revenue was $7.88 million, an increase of 37.48% compared to the previous year's $5.73 million. Losses were -$69.20 million, -21.45% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 89.39% from the latest price.

Price Target

$1.25

(89.39% upside)

Analyst Consensus: Hold